Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth most common global cause of death and also exerts an enormous toll on patient quality of life (1) . Currently, treatment of COPD is suboptimal. In the past, long-term administration of antibiotics was used to treat acute exacerbations of COPD, but metaanalyses of the studies of antibiotic administration showed no significant benefit (2) . A multicenter, crosssectional, observational study was conducted in 30 Spanish hospitals among COPD patients aged > 40 years who were hospitalized for an acute exacerbation showed that antibiotic use was significantly associated with yellow or green-yellow sputum prior to the exacerbation, a higher number of exacerbations in the previous year, more visits to emergency departments, and bronchiectasis (3) . Because of these problems with antibiotic treatment, more and more traditional Chinese physicians are focusing on exploring the therapeutic effect of Chinese herbal medicine in COPD.
Xiaoqinglong decoction (XQLD) was from Shan
Han Lun, a famous formulary in traditional Chinese medicine (4) . The components of XQLD included Ma Huang (9 g), Gui Zhi (6 g), Bai Shao (9 g), Gan Jiang (3 g), Xi Xin (3 g), Zhi Gan Cao (6 g), Ban Xia (9 g) and Wu Wei Zi (3 g) and its major active constituents were ephedrine, cinnamic acid, peoniflorin, methyleugenol, glycyrrhizin and schisandrin. XQLD has been used for asthma, chronic bronchitis, allergic rhinitis, pneumonia, COPD, and sick sinus syndrome therapy for many years. The therapeutic effect of XQLD in COPD patients has received most traditional Chinese physicians' approval. Its side effects are fewer than antibiotics and it will not generate resistance as antibiotics do. Based on these advantages, the usage of XQLD in COPD treatment and related mechanisms have acquired wide attention recently. Its functional mechanism may be related to multiple factors (5) . It was reported that XQLD could inhibit inflammatory cytokines, including IL-4, IL-8, TNF-α, and IFN-γ (6), rectify imbalance of oxidation/anti-oxidation and alleviate inflammatory reactions in COPD rats (4) . And also, it could ameliorate pathological changes of airway inflammation and remodeling in COPD models.
We have also documented that XQLD treatment could significantly lower expression of γ-glutamylcysteine synthetase and nuclear factor-κB in bronchial and alveolar epithelium of COPD rats (4). However, the precise molecular and genetic mechanism of XQLD in COPD therapy remains to be determined. Gene expression profiles of diseased tissues help us to provide insight into the molecular mechanisms of disease and may eventually lead to the identification of novel therapeutic targets. Gene expression profileanalysis has been used in many diseases, including respiratory system diseases, such as acute lung injury (7). In the current study, to evaluate the effect of XQLD on COPD, we established a modified rat COPD model following previous studies described by Nie YC et al. (8) , Song YP et al. (9) , and Sun GR et al. (10) . Differentially expressed genes were screened by a cDNA microarray technique after COPD rats were established to explore effects of XQLD on gene expression profiles. The relationship between alteration of gene expression and disease progress in rats helped us to elucidate the pathogeneses of COPD, understand the mechanisms of XQLD in COPD therapy and explore new potential novel therapeutic targets in COPD.
Materials and Methods

Animals and reagents
Thirty 2-month-old male Wistar rats were purchased from the Center of Medical Experimental Animals of Shandong University (Grade SPF, Certificated SCXK Lu2003004) (Ji'nan, China) and maintained in accordance with guidelines of the committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (DHEW publication No.
[NIH] FS-23) on Animal Care. Animals were divided into 3 experimental groups at random. Twenty rats were used to induce COPD models. Ten animals with this disease received XQLD therapy (therapy group) and the other ten were treated with PBS (model group). Ten normal Wistar rats were used as controls (control group). LPS was obtained from Sigma (St. Louis, MO, USA). Pentobarbital sodium was purchased from China National Medicine Group Shanghai Chemical Reagent Company. Reagents for XQLD were purchased from the pharmacy of Shandong University of Traditional Chinese Medicine. All the herbs were decocted with water and the final concentration was 0.6 g/mL. Sterilization of this decoction was carried out by steam sterilizer.
Experimental procedures
We established a modified rat COPD model following previous studies (8) (9) (10) and the treatment schema is shown in Figure 1 . At first, a normal rat COPD model was established with LPS injection and cigarette smoke (CS) which has been documented to be a reliable COPD model (8) . LPS was injected into rats through the trachea after they were anesthetized with 0.4% pentobarbital sodium (50 mg/kg) at day 1 and day 14. Animals were fixed and their glottises were exposed. An intravenous cannula was inserted into the trachea quickly and its plunger was drawn out. Then it was connected with another syringe. At the zero point two mL (200 μg) LPS, dissolved in normal saline, was pushed into the trachea. Rats were erected immediately and swiveled to distribute LPS in the lungs. CS was given twice a day from day 2 to day 28 (except day 1 and day 14). Nine point zero three grams of a cigarette was burned and CS lasted for 1 h each time. The second CS was given after 4 h. The normal rat COPD model was then modified by keeping rats at −20°C for 5 min/ day from day 22 to day 29 according to the methods described by Sun GR et al. (10) . Sun GR et al. found that there were more inflammatory cell infiltration in the modified rat COPD model than that in the normal rat COPD model from pathological characteristics analysis. Subsequently, rats in the therapy group were drenched with 2 mL XLQD (total dose = 7.5 × clinical dose in adult) from day 30 to day 43 (4) . Rats in the model group were treated with PBS and rats in the control group were held under the same conditions without any intervention.
Observation of trachea ultramicrostructure
At day 44, all animals were sacrificed. 1-1.5 cm upper eminence trachea tissues were collected, and fixed with 2.6. Total RNA extraction and cDNA microarray screening Lung tissues were selected randomly from each group and total RNA was extracted with Trizol (Invitrogen, Carlsbad, CA, USA). RNA was purified with the NucleoSpin RNA clean-up kit (MachereyNagel, Düren, Germany). RNA optical density at 260 nm/280 nm was consistently > 1.8. RNA samples were reverse transcribed into single-strand cDNA, synthesized into double-strand cDNA, and transcribed into cRNA in vitro using the T7RiboMAX Express Large Scale RNA Production System (Promega, Madison, WI, USA). After reverse transcription with random primers, cRNA products were marked with the Klenow enzyme.
Samples were hybridized using a hybridization solution (25% formamide, 3× standard saline citrate [SSC], 0.2% sodium dodecyl sulfate [SDS], 5× Denhart's) at 42°C overnight in a humid environment. Subsequently, slides were washed with washing solution I (2× SSC, 0.2% SDS) at 42°C for 4 min, followed by washing solution II (2× SSC). Arrays were scanned using CapitalBio's confocal scanner LuxScan 10K-A (Beijing, China). An intensitydependent lowess program in the R language package was used to normalize two channel ratio values. Statistical data and differential analysis files were generated by SAM software 3.0 (Stanford University, Stanford, CA, USA). 2% glutaraldehyde for 2 h at 4°C. After washing with PBS, they were fixed for 1 h with osmium tetroxide at 4°C and then washed twice with double distilled water. Following dehydration with alcohol, they were dried. At last, samples were stuck to a metal sample table with paste which can conduct electricity, covered by a metal membrane and then observed using scanning electron microscopy.
Histomorphology performances under light microscope
Paraffin-embedded sections of lung tissue were deparaffinized in xylene and ethanol, stained with hematoxylin-esoin (H&E) and observed under a light microscope (Nikon Corporation, Tokyo, Japan). Trachea pathology grade was judged according to a modified criterion designed by Barbera et al. (11) ( Table 1 ).
General appearances observation and body mass growth index calculation
Animal general appearances were observed during the whole process, which included animal movement, fur appearance, weight growth, respiration situation and cough severity. Animal body mass growth index was calculated as follows: Body mass growth index = (body mass before experiment -body mass after experiment) /body mass before experiment Figure 1 . Schema of treatment. LPS (200 μg) was injected into rats through trachea at day 1 and day 14. CS was given twice per day from day 2 to day 28 (except day 14). Animals were kept at −20°C for 5 min/day from day 22 to day 29. Rats received 2 mL of XQLD therapy daily (0.6 g/mL) from day 30 to day 43. All the animals were sacrificed at day 44. 
Results
Trachea morphology and pathology appearances under scanning electron microscope and light microscope
The scanning electron microscope showed that trachea cilia in the control group were uniform and in the same direction. However, there were lodging, adhesion and depletion with large amounts of secretion in the model group. Compared to the model group, the XQLD therapy group was obviously improved (Figure 2A Table 2 and Figure 2B . There were severe inflammatory responses in the model group and increased lymphocytes, monocytes and neutrophils can be seen in lung tissues. This phenomenon was accompanied by cilia lodging, adhesion and depletion, epithelial cell degeneration, necrosis and desquamate, goblet cell proliferation, epithelial squamous metaplasia, mucous hyperemia and swelling. These pathological changes confirmed that our COPD models were established successfully. After XQLD therapy, inflammatory responses were obviously relieved and the numbers of inflammatory cells, including lymphocytes, monocytes, and neutrophils, decreased significantly. Meanwhile, pathological changes of cilia, epithelial cells, goblet cells, epithelium and mucous membranes were dramatically relieved.
General appearances
Rats in the control group were active and restless, with smooth and burnished fur. Their body mass increased gradually and respiration was stable. Before XQLD therapy, rats in the model group and therapy group usually stayed still, extradoed and wriggled with gathered fur. Their body mass increased slowly and respiration was short accompanied by frequent cough. Cough appeared at the first day of CS and lasted to the end of our experiment. At day 28, rats in the model group and therapy group appeared to have shortness of breath. These symptoms of rats in the therapy group were obviously alleviated after XQLD therapy. Body mass growth indexes in the three groups are shown in Figure 3 .
Analysis of gene expression profiles
Genes were judged to be differentially expressed genes when the mean value exceeded 2.5 or lower than 0.375 to increase research reliability. A comparison of gene expression between model group and control group indicated that there were 56 differentially expressed genes which included 32 up-regulated genes and 24 down-regulated genes. The known genes are shown in Table 3 . Comparison of gene expression between therapy group and control group showed that there were only 11 differentially expressed genes, including 5 up-regulated genes (3 of them were also up-regulated genes in model group) and 6 down-regulated genes. Our data indicated that expression of 29 up-regulated genes and 24 down-regulated genes were modified by XQLD therapy and there was no difference when these genes expression were compared to their expression in control group. A functional classification of the differentially expressed genes between model group and control group is shown in Figure 4 . The number of differently expressed genes related to immune and inflammation responses is the largest except for not classified and functionally unclassified genes. Other differently expressed genes were involved in metabolism, gene expression, cell transportation, cell cycle, and cell proliferation.
Discussion
CS represents the most important environmental risk factors for respiratory diseases and it is the first risk for COPD (12, 13) . However, it needs a long time to establish rat COPD models with CS only. LPS is the major component of Gram-negative bacterium adventitia. It can damage airway epithelium directly, activate macrophages, lymphocytes, and neutrophils, induce bronchi chronic inflammation and cause emphysema formation. It stimulates secretion of specific pro-inflammatory molecules from circulating monocytes, such as IL-6 and monocyte chemotactic protein-1, and thereby aggravates progress of COPD (14) . In this study, the COPD model was established by a modified method of combining fumigation and lipopolysaccharide (LPS) intra-tracheal dripping (4) . Pathology appearances under a scanning electron Model group, rat COPD models treated with PBS; Therapy group, rat COPD models received Xiaoqinglong decoction therapy; Control group, Wistar rats without any treatment.
Model group
Grade microscope and light microscope showed lesions in the rat model closely resemble COPD lesions occurring in humans.
Nutritional status disorders are the most common extra-pulmonary manifestations of COPD. A specific loss of weight, characterized by lean body mass (LBS), is observed in some COPD patients (15) . In our study, animals in the model group and therapy group showed lower weight growth indexes than those in the control group (p < 0.01). Compared with the model group, the changes of general appearance, including LBS, in the therapy group demonstrated that XQLD was an effective drug which can relieve COPD symptoms.
Modern pharmacology studies have indicated that XQLD could down-regulate expression of γ-glutamylcysteine synthetase and nuclear factor-κB in bronchial and alveolar epithelium of COPD rats, which maybe responsible for gene expression regulation through multiple mechanisms. Our gene expression profiles analysis showed that the number of differently expressed genes between the model group and control group was 56 while there were only 11 differently expressed genes in the therapy group when compared to the control group. The genes involved were in immune and inflammation reactions, metabolism, cell transportation and cell cycle, signal transduction and gene regulation. Twenty-nine up-regulated genes and 24 down-regulated genes in the model group became non-differentially expressed genes after XQLD therapy. The changes of genes expression after XQLD treatment reflected that complicated genetic regulations were involved in the progression of COPD.
D i ff e r e n t i a l l y e x p r e s s e d g e n e s r e l a t e d t o immune response and inflammation mainly included immunoglobulin heavy chain 1a (serum IgG2a), arginase 1, alpha 2,6-sialyltransferase, leukotriene A4 hydrolase, FK506 binding protein 9 (FKBP9), and CEA-related cell adhesion molecule-1 (CEACAM-1). It is known that serum IgG2a (J chain) is a small polypeptide, which regulates polymer formation of immunoglobulin (Ig)A and IgM (16) . Arginase-1 is an enzyme in arginine metabolism which plays an important role in asthma by decreasing nitric oxide production and increasing formation of peroxynitrite, polyamines and l-proline (17) . Alpha 2,6-sialyltransferase is an acute-phase reactant and it is a Golgi membrane-bound enzyme (18) . The leukotrienes are a family of lipid mediators involved in inflammation and allergy. Leukotriene B4 modulates immune responses, participates in the host defense against infections, and is a key mediator of PAFinduced lethal shock. The final step in the biosynthesis of leukotriene B4 is catalyzed by leukotriene A4 hydrolase, a unique bifunctional zinc metalloenzyme with an anion-dependent aminopeptidase activity (19) . Immunoglobulin heavy chain 1a (serum IgG2a), arginase 1, alpha 2,6-sialyltransferase and leukotriene A4 hydrolase were up-regulated when COPD occurred. FK506 (tacrolimus), has powerful immunosuppressant properties and it can promote nerve regeneration (20) . (21) and plays an immunosuppression role. CEACAM1 appears to play a unique role among the neutrophil CEACAMs (22) . Both FKBP9 and CEACAM1 genes were down-regulated in the model group compared to the control group. There were also some differentially expressed genes related to gene expression regulation in the model group when compared to the control group. These genes included nuclear pore protein p62 (Nup62), neuronal PAS domain protein 2 (NPAS2) and the α-subunit of eukaryotic initiation factor 2B (eIF-2B). Transcription factor Sp1 plays an important role in the expression of many cellular genes and it must interact with p62, through its C-terminus, to bring transcribeable DNA in contact with the transcription factors (23) . In COPD rats, increased expression of p62 suggested up-regulated transcription of some genes. NPAS2 is a transcription factor expressed primarily in the mammalian forebrain (24) and it is an important transcription factor associated with circadian rhythms (25) . Phosphorylation of eIF-2 is one of the best known mechanisms regulating protein synthesis in a wide range of eukaryotic cells, from yeast to human (26) . In COPD rat models, NPAS2 and eIF-2 were negatively regulated but their roles in COPD are still unclear.
Some other differentially expressed genes between the model group and control group had a relationship with metabolism and signal transduction. Fructose-bisphosphate aldolase A (Muscle-type aldolase) involved in glycometabolism, was upregulated while 6-pyruvoyl-tetrahydropterin synthase, 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 and acyl-coA oxidase were down-regulated. Differentially expressed genes associated with signal transduction included epidermal growth factor (EGF)-related peptides and phosphatidylinositol 3-kinase catalytic subunit α (PIK3CA). Both of these were downregulated while their expression had no significant differencebetween the therapy group and control group. And also, there were some genes whose functions were not clear. They perhaps played a novel or important role in COPD genesis and development. Further study is still needed to explore these unknown genes.
Conclusion
Our results showed XQLD was an effective drug for COPD treatment and its function was related to gene expression alteration. A functional classification of differentially expressed genes indicated complex mechanisms involved in the genesis and development of COPD. Our results facilitate further investigation of the molecular mechanisms underlying the genesis and development of COPD and help us to understand mechanisms of XQLD in COPD therapy. 
